结直肠癌筛查:粪便免疫化学检测、乙状结肠镜或结肠镜:临床实践指南
该指南针对50-79岁、无症状且预期寿命至少15年的未筛查成人,基于15年随访证据评估四种筛查方案。对15年结直肠癌风险低于3%者建议不筛查(弱推荐);风险高于3%者建议每年或每两年一次粪便免疫化学检测、单次乙状结肠镜或单次结肠镜筛查(弱推荐)。证据总体确定性低,强调共同决策。
要点
- 适用于50-79岁、无既往筛查、无症状且预期寿命至少15年的成人。
- 15年结直肠癌风险低于3%者,建议不筛查(弱推荐)。
- 15年风险高于3%者,建议四种方案之一筛查(弱推荐)。
核心结论
- 基于获益、伤害和负担,指南小组推断多数15年结直肠癌风险≥3%的知情个体可能选择筛查,而风险低于3%者可能拒绝筛查。
- 鉴于价值观和偏好不同,最佳照护需要共同决策。
研究设计与样本
- 指南小组包括患者、临床医生、内容专家和方法学家,使用GRADE并遵循可信指南标准制定推荐。
- 进行了关联的系统评价(结直肠癌筛查试验)和微观模拟建模,以告知小组15年筛查获益和伤害。
- 小组还审查了每种筛查方案的实际问题和负担,并根据自身经验估计人群典型成员为选择筛查所看重的获益幅度,使用获益阈值来指导推荐。
主要发现
- 总体而言,关于筛查的15年获益、负担和伤害存在大量不确定性(低确定性证据)。
- 最佳估计提示所有四种筛查方案在降低结直肠癌死亡率方面结果相似。
- 每两年一次FIT可能在15年内对癌症发病率影响很小或无影响,而每年一次FIT、乙状结肠镜和结肠镜可能降低癌症发病率。
- 对于FIT,与乙状结肠镜和结肠镜相比,发病率降低幅度较小。
- 筛查相关的严重胃肠道和心血管不良事件罕见。
关键数值与推荐
- 对估计15年结直肠癌风险低于3%的个体,建议不筛查(弱推荐)。
- 对估计15年风险高于3%的个体,建议采用以下四种筛查方案之一:每年一次FIT、每两年一次FIT、单次乙状结肠镜或单次结肠镜(弱推荐)。
临床怎么用
- 推荐适用于50-79岁、无既往筛查、无结直肠癌症状且预期寿命至少15年的成人。
- 对于15年结直肠癌风险低于3%的个体,建议不筛查(弱推荐)。
- 对于15年风险高于3%的个体,建议采用每年一次FIT、每两年一次FIT、单次乙状结肠镜或单次结肠镜筛查(弱推荐)。
局限性
- 总体而言,关于筛查的15年获益、负担和伤害存在大量不确定性(低确定性证据)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CLINICAL QUESTION: Recent 15-year updates of sigmoidoscopy screening trials provide new evidence on the effectiveness of colorectal cancer screening. Prompted by the new evidence, we asked: "Does colorectal cancer screening make an important difference to health outcomes in individuals initiating screening at age 50 to 79? And which screening option is best?" CURRENT PRACTICE: Numerous guidelines recommend screening, but vary on recommended test, age and screening frequency. This guideline looks at the evidence and makes recommendations on screening for four screening options: faecal immunochemical test (FIT) every year, FIT every two years, a single sigmoidoscopy, or a single colonoscopy. RECOMMENDATIONS: These recommendations apply to adults aged 50-79 years with no prior screening, no symptoms of colorectal cancer, and a life expectancy of at least 15 years. For individuals with an estimated 15-year colorectal cancer risk below 3%, we suggest no screening (weak recommendation). For individuals with an estimated 15-year risk above 3%, we suggest screening with one of the four screening options: FIT every year, FIT every two years, a single sigmoidoscopy, or a single colonoscopy (weak recommendation). With our guidance we publish the linked research, a graphic of the absolute harms and benefits, a clear description of how we reached our value judgments, and linked decision aids. HOW THIS GUIDELINE WAS CREATED: A guideline panel including patients, clinicians, content experts and methodologists produced these recommendations using GRADE and in adherence with standards for trustworthy guidelines. A linked systematic review of colorectal cancer screening trials and microsimulation modelling were performed to inform the panel of 15-year screening benefits and harms. The panel also reviewed each screening option's practical issues and burdens. Based on their own experience, the panel estimated the magnitude of benefit typical members of the population would value to opt for screening and used the benefit thresholds to inform their recommendations. THE EVIDENCE: Overall there was substantial uncertainty (low certainty evidence) regarding the 15-year benefits, burdens and harms of screening. Best estimates suggested that all four screening options resulted in similar colorectal cancer mortality reductions. FIT every two years may have little or no effect on cancer incidence over 15 years, while FIT every year, sigmoidoscopy, and colonoscopy may reduce cancer incidence, although for FIT the incidence reduction is small compared with sigmoidoscopy and colonoscopy. Screening related serious gastrointestinal and cardiovascular adverse events are rare. The magnitude of the benefits is dependent on the individual risk, while harms and burdens are less strongly associated with cancer risk. UNDERSTANDING THE RECOMMENDATION: Based on benefits, harms, and burdens of screening, the panel inferred that most informed individuals with a 15-year risk of colorectal cancer of 3% or higher are likely to choose screening, and most individuals with a risk of below 3% are likely to decline screening. Given varying values and preferences, optimal care will require shared decision making.
引用
- Helsingen LM, Vandvik PO, Jodal HC, et al. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. BMJ. 2019. PMID: 31578196. doi:10.1136/bmj.l5515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。